Research on type 2 sodium glucose co-transporters in diabetes treatment

DING Hai-feng; CAO Yong-bing; AN Mao-mao; JIA Xin-ming; JIANG Yuan-ying

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

In the last few years, inhibitors of the type 2 sodium glucose co-transporters (SGLT2) had been the subject of novel approach to treating diabetes. SGLT2 played a major role in physiology of glucose reabsorption from proximal part of kidney. The blockade of SGLT2 in the kidney had the potential to prompts urinary excretion of glucose and promotes normalization of blood glucose without hypoglycemia in the setting of type 2 diabetes. Clinical trails showed that their efficacy in the treatment of type 2 diabetes was promising; Weight loss and very low risk of hypoglycemia were the potential benefits of these inhibitors. Some of these inhibitors had been developed and advanced to late phase clinical testing.

Research on type 2 sodium glucose co-transporters in diabetes treatment

The center of new drug development, second military medical university, Shanghai 200433, China

Received Date: 2010-11-09

Rev Recd Date: 2011-02-22

Key words:

Abstract: In the last few years, inhibitors of the type 2 sodium glucose co-transporters (SGLT2) had been the subject of novel approach to treating diabetes. SGLT2 played a major role in physiology of glucose reabsorption from proximal part of kidney. The blockade of SGLT2 in the kidney had the potential to prompts urinary excretion of glucose and promotes normalization of blood glucose without hypoglycemia in the setting of type 2 diabetes. Clinical trails showed that their efficacy in the treatment of type 2 diabetes was promising; Weight loss and very low risk of hypoglycemia were the potential benefits of these inhibitors. Some of these inhibitors had been developed and advanced to late phase clinical testing.

HTML

Reference (19)

[1]	Wright EM,Hirayama BA,Loo DF.Active sugar transport in health and disease[J].Intern Med,2007,261:32.
[2]	Kanai Y,Lee WS,You G,et al.The human kidney low affinity Na/glucose cotransporter SGLT2: delineation of the major renal reabsorptive mechanism for D-glucose[J].Clin Investig,1994,93:397.
[3]	Van den Heuvel LP,Assink K,Willemsen M,et al.Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2) [J].Hum Genet,2002,111:544.
[4]	Calado J,Soto K,Clemente C,et al.Novel compound heterozygous mutations in SLC5A2 are responsible for autosomal recessive renal glucosuria[J].Hum Genet,2004, 114:314.
[5]	Pajor A,Wright EM.Cloning and functional expression of a mammalian Na⁺/nucleoside cotransporter. A member of the SGLT family[J].Biol Chem,1992,267:3557.
[6]	Wright EM.Renal Na⁺-glucose cotransporters[J].Am J Physiol,2001,280:F10.
[7]	Turk E,Zabel B,Mundlos S,et al.Glucose/galactose malabsorption caused by a defect in the Na⁺/glucose cotransporter[J].Nature,1991,350:354.
[8]	Pajor AM,Randolph KM,Kerner SA,et al.Inhibitor binding in the human renal low-and high-affinity Na⁺/glucose cotransporters[J].J Pharmacol Exp Ther,2008,324:985.
[9]	Ehrenkranz JRL,Lewis NG,Kahn CR,et al.Phlorizin: a review[J].Diabetes Metab Res Rev,2005,21:31.
[10]	Oku A,Ueta K,Arakawa K,et al.T-1095, an inhibitor of renal Na⁺- glucose cotransporters, may provide a novel approach to treating diabetes[J].Diabetes,1999, 48:1794.
[11]	Adachi T,Yasuda K,Okamoto Y,et al.T-1095, renal Na⁺-glucose transporter inhibitor, improves hyperglycemia in streptozotocin induced diabetic rats[J].Metabolism,2000,49:990.
[12]	Katsuno K,Fujimori Y,Takemura Y,et al.Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level[J].Pharmacol Exp Ther,2007,320:323.
[13]	Hussey EK,Clark RV,Amin DM,et al.Early clinical studies to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of sergliflozin, a novel inhibitor of renal glucose reabsorption, in healthy volunteers and subjects with type 2 diabetes mellitus[J].Diabetes,2007,56 (Suppl 1):189.
[14]	Fujimori Y,Katsuno K,Nakashima I,et al.Remogliflozin etabonate, in a novel category of selective low-affinity/high-capacity sodium glucose cotransporter (SGLT-2) inhibitors, exhibits antidiabetic efficacy in rodent models[J].Pharmacol Exp Ther,2008,327:268.
[15]	Wei M,Bruce AE,Alexandra AN,et al.Discovery of dapagliflozin: A potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes[J].J Med Chem,2008,51(5):1145.
[16]	Komoroski B,Vachharajani N,Boulton D,et al.Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects[J].Clin Pharmacol Ther,2009,85:520.
[17]	Komoroski B,Vachharajani N,Feng Y,et al.Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus[J].Clin Pharmacol Ther,2009,85:513.
[18]	List JF,Woo V,Morales E,et al.Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes mellitus[J].Diabetes Care,2009,32:650.
[19]	Calado J,Loeffler J,Sakalliouglu O,et al.Familial renal glucosuria: SGLC5A2 mutation analysis and evidence of salt-wasting[J].Kidney Int,2006,69:852.

Message Board

Research on type 2 sodium glucose co-transporters in diabetes treatment

Abstract

References

Proportional views

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Related

Proportional views